Trials / Completed
CompletedNCT00646841
Effects of Doxazosin Gastrointestinal Therapeutic System on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensive Patients
The Effects of Doxazosin Gastrointestinal Therapeutic System (GITS) on Ambulatory Blood Pressure and Cardiovascular Risk Factors in Uncontrolled Hypertensives on Drug Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 89 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective was to determine the effects of the Gastrointestinal Therapeutic System (GITS) formulation of Doxazosin when used in combination therapy with the 5 major classes of antihypertensive agents as measure by 24-hour diastolic blood pressure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Doxazosin gastrointestinal therapeutic system (GITS) | 4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6). |
Timeline
- Start date
- 2003-02-01
- Primary completion
- 2004-02-01
- Completion
- 2004-02-01
- First posted
- 2008-03-31
- Last updated
- 2021-01-29
Locations
7 sites across 3 countries: Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00646841. Inclusion in this directory is not an endorsement.